scholarly journals Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma

2020 ◽  
Vol 122 (12) ◽  
pp. 1818-1824 ◽  
Author(s):  
Lehel Peterfi ◽  
Daniel Banyai ◽  
Maria V. Yusenko ◽  
Thea Bjercke ◽  
Gyula Kovacs
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Conventional Renal Cell Carcinoma

743: Resection of Nodal Disease in Patients with Metastatic Conventional Renal Cell Carcinoma Improves Survival

2006 ◽  
Vol 175 (4S) ◽  
pp. 241-242 ◽  
Author(s):  
Stephen Brassell ◽  
Ricardo F. Sanchez-Ortiz ◽  
Surena F. Matin ◽  
David A. Swanson ◽  
Christopher G. Wood
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Nodal Disease ◽  
Conventional Renal Cell Carcinoma

KIBRA plays as tumour suppressor via phosphorylation of LATS-2 in conventional renal cell carcinoma tissues

2021 ◽  
Vol 79 ◽  
pp. S752
Author(s):  
K. Mitsunari ◽  
Y. Miyata ◽  
T. Matsuo ◽  
K. Ohba ◽  
Y. Mukae ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumour Suppressor ◽  
Conventional Renal Cell Carcinoma

scholarly journals Identification of Proteins Differentially Expressed in the Conventional Renal Cell Carcinoma by Proteomic Analysis

2005 ◽  
Vol 20 (3) ◽  
pp. 450 ◽  
Author(s):  
Jeong Seok Hwa ◽  
Hyo Jin Park ◽  
Jae Hun Jung ◽  
Sung Chul Kam ◽  
Hyung Chul Park ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proteomic Analysis ◽  
Renal Cell ◽  
Differentially Expressed ◽  
Conventional Renal Cell Carcinoma

scholarly journals Dual role of KRT17: development of papillary renal cell tumor and progression of conventional renal cell carcinoma

2019 ◽  
Vol 10 (21) ◽  
pp. 5124-5129 ◽  
Author(s):  
Donat Peter Sarlos ◽  
Maria V Yusenko ◽  
Lehel Peterfi ◽  
Arpad Szanto ◽  
Gyula Kovacs
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Dual Role ◽  
Cell Tumor ◽  
Conventional Renal Cell Carcinoma

scholarly journals Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma

2016 ◽  
Vol 10 (9-10) ◽  
pp. 306
Author(s):  
Gregory W. Hosier ◽  
Matthew T. Roberts
Keyword(s):  
Renal Cell Carcinoma ◽  
Glutamic Acid ◽  
Cell Carcinoma ◽  
Metastatic Melanoma ◽  
Renal Cell ◽  
Specific Inhibitor ◽  
Initial Response ◽  
Selective Inhibitor ◽  
Complete Regression ◽  
Conventional Renal Cell Carcinoma

Vemurafenib is a selective inhibitor of overactive BRAF oncogene with a substitution of lysine for glutamic acid at residue 600 (BRAFV600E), a mutation expressed in approximately 50% of all melanomas. We report a case of a patient with metastatic melanoma treated with vemurafenib, who subsequently presented with a biopsy-proven conventional renal cell carcinoma (RCC). We observed an initial complete regression of the mass while on vemurafenib. This was unexpected, given that vemurafenib is a specific inhibitor of BRAFV600E and most RCCs do not harbour this mutation.

Sign in / Sign up

Export Citation Format

Share Document